Efficacy, Safety, Tolerability of AXA1125 in Fatigue After COVID-19 Infection
NCT05152849
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
41
Enrollment
INDUSTRY
Sponsor class
Conditions
Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection
Interventions
DRUG:
AXA1125
DRUG:
Placebo
Sponsor
Axcella Health, Inc